{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T16:27:27Z","timestamp":1709742447124},"reference-count":26,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2008,8,18]],"date-time":"2008-08-18T00:00:00Z","timestamp":1219017600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Transplantation"],"published-print":{"date-parts":[[2009,1]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold><jats:bold> Introduction:\u2002<\/jats:bold> To assess the efficacy of calcineurin inhibitor (CNI)\u2010free immunosuppression vs. calcineurin\u2010based immunosuppression in patients receiving expanded criteria donor (ECD) kidneys.<\/jats:p><jats:p><jats:bold>Patient and methods:\u2002<\/jats:bold> Thirteen recipients of ECD kidneys were enrolled in this pilot study and treated with induction therapy and maintained on sirolimus, mycophenolate mofetil (MMF) and prednisone. A contemporaneous control group was randomly selected comprised of 13 recipients of ECD kidneys who had been maintained on CNI plus MMF and prednisone.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> For the study group vs. the control group, two\u2010yr graft survival was 92.3% vs<jats:italic>.<\/jats:italic> 84.6% (p\u2003=\u2003NS), two\u2010yr patient survival was 100% vs. 92.3% (p\u2003=\u2003NS) and the acute rejection rates were 23% vs. 31% (p\u2003=\u2003NS), respectively. Renal function was significantly better in the study group compared with control up to the six\u2010month mark, after which, it remained numerically but not statistically significant. Complications were more common in the study group, but serious adverse events requiring discontinuation were rare.<\/jats:p><jats:p><jats:bold>Conclusion:\u2002<\/jats:bold> This pilot study demonstrates that CNI\u2010free regimens can be safely implemented in patients receiving ECD kidneys with excellent two\u2010yr patient and graft survival and good renal allograft function. Longer follow\u2010up in larger randomized controlled trials are necessary to establish these findings.<\/jats:p>","DOI":"10.1111\/j.1399-0012.2008.00880.x","type":"journal-article","created":{"date-parts":[[2009,2,17]],"date-time":"2009-02-17T12:26:34Z","timestamp":1234873594000},"page":"9-15","source":"Crossref","is-referenced-by-count":8,"title":["Immunosuppression without calcineurin inhibition: optimization of renal function in expanded criteria donor renal transplantation"],"prefix":"10.1111","volume":"23","author":[{"given":"Patrick P.W.","family":"Luke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher Y.","family":"Nguan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Horovitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Gregor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff","family":"Warren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew A.","family":"House","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,1,19]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1991.tb02641.x"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199701150-00008"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02480-6"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200210270-00002"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.01177.x"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2004.00627.x"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000258586.52777.4c"},{"key":"e_1_2_7_9_2","volume-title":"Scientific Registry of Transplant Recipients: OPTN\/SRTR 2005 Annual Report","year":"2007"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V123589"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199801270-00010"},{"key":"e_1_2_7_12_2","volume-title":"UNOS Policy 3.5.1. Definition of Expanded Criteria Donor and Standard Donor","author":"United Network for Organ Sharing","year":"2006"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060068"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000219703.39149.85"},{"key":"e_1_2_7_15_2","first-page":"CD004290","article-title":"Target of rapamycin inhibitors (TOR\u2010I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients","volume":"2","author":"Webster AC","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199904150-00017"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01658.x"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)11606-0"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0012.17.s9.5.x"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2006.00583.x"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2006.10.035"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2004.02.011"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2007.01671.x"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2004.00332.x"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000128636.70499.6E"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000231505.91988.26"},{"key":"e_1_2_7_27_2","first-page":"762","article-title":"The pleiotropic effects of mTor inhibitors","volume":"17","author":"Ponticelli C","year":"2004","journal-title":"J Nephrol"}],"container-title":["Clinical Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-0012.2008.00880.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1399-0012.2008.00880.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:44:55Z","timestamp":1696898695000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-0012.2008.00880.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["10.1111\/j.1399-0012.2008.00880.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1399-0012.2008.00880.x","archive":["Portico"],"relation":{},"ISSN":["0902-0063","1399-0012"],"issn-type":[{"value":"0902-0063","type":"print"},{"value":"1399-0012","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}